Suchergebnisse - "Gabay, Cem"

PubPharm (484)

61

Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis

enthalten in: Arthritis Research & Therapy | 2020

von Jarlborg, M. | Courvoisier, D. | Lamacchia, C. | +6

62

Response to : 'When binary and continuous responses disagree' by Dr Ouyang

enthalten in: Annals of the rheumatic diseases | 2020

von Lauper, K. | Courvoisier, D. | Gabay, C.

CommentOn: . - PMID 29730637

63

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

enthalten in: Arthritis research & therapy | 2020

von Gabay, C. | Burmester, G. | Strand, V. | +8

64

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

enthalten in: Arthritis Research & Therapy | 2020

von Gabay, C. | Burmester, G. | Strand, V. | +8

65

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

enthalten in: Arthritis Research & Therapy | 2020

von Gabay, C. | Burmester, G. | Strand, V. | +8

66

enthalten in: Revue medicale suisse | 2020

von Hügle, T. | Gabay, C.

67

Intracellular IL-1 Receptor Antagonist Isoform 1 Released from Keratinocytes upon Cell Death Acts as an Inhibitor for the Alarmin IL-1α

enthalten in: Journal of immunology (Baltimore, Md. : 1950) | 2020

von Martin, P. | Palmer, G. | Rodriguez, E. | +4

68

Individual therapeutic DAS28-$ d_{crit} $ responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies

enthalten in: Rheumatology international | 2020

von Koehm, M. | McIntosh, M. | Hofmann, M. | +6

69

Individual therapeutic DAS28-$ d_{crit} $ responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies

enthalten in: Rheumatology international | 2020

von Koehm, M. | McIntosh, M. | Hofmann, M. | +6

70

Individual therapeutic DAS28-$ d_{crit} $ responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies

enthalten in: Rheumatology international | 2020

von Koehm, M. | McIntosh, M. | Hofmann, M. | +6